Canada's Bausch Health Q1 revenue rises

Bausch Health Companies

29/04/2026 21:52

Overview

Canada pharmaceutical firm's Q1 revenue rose 12%, beating analyst expectations

Adjusted EBITDA for Q1 rose 27%, beating analyst expectations

Company posted $1.43 bln net loss due to goodwill impairment charge

Outlook

Bausch Health sees 2026 consolidated revenue of $10.67 bln to $10.92 bln

Company expects 2026 consolidated adjusted EBITDA of $3.885 bln to $4.01 bln

Company says uncertainty around tariffs may affect business performance in 2026

Result Drivers

SALIX SEGMENT GROWTH - Revenue in Salix segment rose 18%, driven by 21% growth in Xifaxan sales

SOLTA MEDICAL EXPANSION - Solta Medical revenue increased 51%, aided by the acquisition of Shibos full service aesthetics business in China and organic growth in APAC

DIVERSIFIED SEGMENT DECLINE - Diversified segment revenue fell 10% on both reported and organic basis

Company press release: ID:nPnc1FG6ka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$2.52 bln
$2.41 bln (4 Analysts)
Q1 EPS
-$3.82
Q1 Net Income
-$1.43 bln
Q1 Adjusted EBITDA
Beat
$837 mln
$756.67 mln (3 Analysts)
Q1 Operating Income
-$950 mln
Q1 Pretax Profit
-$1.35 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 2 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)